GLPwatch
Point-of-Care Ultrasound Aids in the Management of Patient Taking Semaglutide Before Surgery: A Case Report.
A A Pract · 2024
Last updated 2026-05-28A patient taking semaglutide, a GLP-1 drug, was assessed before surgery using a point-of-care ultrasound to check stomach contents. The ultrasound helped identify a higher risk of stomach contents entering the lungs during anesthesia, allowing the medical team to adjust the anesthesia plan accordingly.
AI summary of the abstract below.
| Journal | A A Pract, 2024 |
|---|---|
| Citations | 4 |
| Relative citation ratio | 1.27 |
| NIH percentile | 59 |
| Molecules | semaglutide |
| Conditions studied | Obesity |
Abstract
Semaglutide, a glucagon-like peptide-1 (GLP-1) analog, has various effects on the gastrointestinal tract. In patients undergoing anesthesia delayed gastric emptying time can have sequelae if not identified preoperatively. Modalities include thorough history regarding the last dose administration of a GLP-1 analog and ultrasound of gastric contents before induction of anesthesia. We present a case in which gastric ultrasound identified a patient at increased risk for aspiration on induction and allowed for appropriate alterations in the anesthetic plan.
Verbatim abstract via PubMed 38498670 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.